[1] |
AXELROD DA, SCHNITZLER MA, XIAO H, et al. An economic assessment of contemporary kidney transplant practice[J]. Am J Transplant, 2018, 18(5): 1168-1176. DOI: 10.1111/ajt.14702.
|
[2] |
黄洁夫. 中国器官移植发展报告(2019)[M]. 北京: 清华大学出版社, 2020.
|
[3] |
HART A, LENTINE KL, SMITH JM, et al. OPTN/SRTR 2019 annual data report: kidney[J]. Am J Transplant, 2021, 21(Suppl 2): 21-137. DOI: 10.1111/ajt.16502.
|
[4] |
JORDAN SC, CHOI J, KAHWAJI J, et al. Progress in desensitization of the highly HLA sensitized patient[J]. Transplant Proc, 2016, 48(3): 802-805. DOI: 10.1016/j.transproceed.2015.11.027.
|
[5] |
CHOI AY, MANOOK M, OLASO D, et al. Emerging new approaches in desensitization: targeted therapies for HLA sensitization[J]. Front Immunol, 2021, 12: 694763. DOI: 10.3389/fimmu.2021.694763.
|
[6] |
ZANATTA E, COZZI M, MARSON P, et al. The role of plasma exchange in the management of autoimmune disorders[J]. Br J Haematol, 2019, 186(2): 207-219. DOI: 10.1111/bjh.15903.
|
[7] |
SPEER C, KÄLBLE F, NUSSHAG C, et al. Outcomes and complications following ABO-incompatible kidney transplantation performed after desensitization by semiselective immunoadsorption - a retrospective study[J]. Transpl Int, 2019, 32(12): 1286-1296. DOI: 10.1111/tri.13482.
|
[8] |
PAVENSKI K, BUCHOLZ M, CHEATLEY PL, et al. The first North American experience using glycosorb immunoadsorption columns for blood group-incompatible kidney transplantation[J]. Can J Kidney Health Dis, 2020, 7: 1-6. DOI: 10.1177/2054358120962586.
|
[9] |
MONTAGUD-MARRAHI E, REVUELTA I, CUCCHIARI D, et al. Successful use of nonantigenspecific immunoadsorption with antihuman Ig-columns in kidney graft antibody-mediated rejection[J]. J Clin Apher, 2020, 35(3): 188-199. DOI: 10.1002/jca.21779.
|
[10] |
JAMBON F, MERVILLE P, GUIDICELLI G, et al. Efficacy of plasmapheresis and semi-selective immunoadsorption for removal of anti-HLA antibodies[J]. J Clin Apher, 2021, 36(3): 291-298. DOI: 10.1002/jca.21858.
|
[11] |
CHAUHAN K, MEHTA AA. Rituximab in kidney disease and transplant[J]. Animal Model Exp Med, 2019, 2(2): 76-82. DOI: 10.1002/ame2.12064.
|
[12] |
SOOD P, HARIHARAN S. Anti-CD20 blocker rituximab in kidney transplantation[J]. Transplantation, 2018, 102(1): 44-58. DOI: 10.1097/TP.0000000000001849.
|
[13] |
GENBERG H, HANSSON A, WERNERSON A, et al. Pharmacodynamics of rituximab in kidney allotransplantation[J]. Am J Transplant, 2006, 6(10): 2418-2428. DOI: 10.1111/j.1600-6143.2006.01497.x.
|
[14] |
KAEGI C, WUEST B, SCHREINER J, et al. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders[J]. Front Immunol, 2019, 10: 1990. DOI: 10.3389/fimmu.2019.01990.
|
[15] |
GALEOTTI C, KAVERI SV, BAYRY J. IVIG-mediated effector functions in autoimmune and inflammatory diseases[J]. Int Immunol, 2017, 29(11): 491-498. DOI: 10.1093/intimm/dxx039.
|
[16] |
PERROTTET N, FERNÁNDEZ-RUIZ M, BINET I, et al. Infectious complications and graft outcome following treatment of acute antibody-mediated rejection after kidney transplantation: a nationwide cohort study[J]. PLoS One, 2021, 16(4): e0250829. DOI: 10.1371/journal.pone.0250829.
|
[17] |
MADDUR MS, STEPHEN-VICTOR E, DAS M, et al. Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy[J]. J Neuroinflammation, 2017, 14(1): 58. DOI: 10.1186/s12974-017-0818-5.
|
[18] |
STEGALL MD, GLOOR J, WINTERS JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody[J]. Am J Transplant, 2006, 6(2): 346-351. DOI: 10.1111/j.1600-6143.2005.01178.x.
|
[19] |
ABU JAWDEH BG, CUFFY MC, ALLOWAY RR, et al. Desensitization in kidney transplantation: review and future perspectives[J]. Clin Transplant, 2014, 28(4): 494- 507. DOI: 10.1111/ctr.12335.
|
[20] |
COLLIN M, BJÖRCK L. Toward clinical use of the IgG specific enzymes IdeS and EndoS against antibodymediated diseases[J]. Methods Mol Biol, 2017, 1535: 339- 351. DOI: 10.1007/978-1-4939-6673-8_23.
|
[21] |
LORANT T, BENGTSSON M, EICH T, et al. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients[J]. Am J Transplant, 2018, 18(11): 2752-2762. DOI: 10.1111/ajt.14733.
|
[22] |
KJELLMAN C, MALDONADO AQ, SJÖHOLM K, et al. Outcomes at 3 years post-transplant in imlifidasedesensitized kidney transplant patients[J]. Am J Transplant, 2021, DOI: 10.1111/ajt.16754[Epubaheadofprint].
|
[23] |
SLATINSKA J, SLAVCEV A, HONSOVA E, et al. Efficacy and safety of bortezomib treatment for refractory acute antibody-mediated rejection-a pilot study[J]. HLA, 2018, 92(Suppl 2): 47-50. DOI: 10.1111/tan.13387.
|
[24] |
PEARL MH, NAYAK AB, ETTENGER RB, et al. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection[J]. Pediatr Nephrol, 2016, 31(8): 1341-1348. DOI: 10.1007/s00467-016-3319-3.
|
[25] |
WOODLE ES, SHIELDS AR, EJAZ NS, et al. Prospective iterative trial of proteasome inhibitor-based desensitization[J]. Am J Transplant, 2015, 15(1): 101-118. DOI: 10.1111/ajt.13050.
|
[26] |
JEONG JC, JAMBALDORJ E, KWON HY, et al. Desensitization using bortezomib and highdose immunoglobulin increases rate of deceased donor kidney transplantation[J]. Medicine (Baltimore), 2016, 95(5): e2635. DOI: 10.1097/MD.0000000000002635.
|
[27] |
ESKANDARY F, REGELE H, BAUMANN L, et al. A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection[J]. J Am Soc Nephrol, 2018, 29(2): 591-605. DOI: 10.1681/ASN.2017070818.
|
[28] |
MORENO GONZALES MA, GANDHI MJ, SCHINSTOCK CA, et al. 32 doses of bortezomib for desensitization is not well tolerated and is associated with only modest reductions in anti-HLA antibody[J]. Transplantation, 2017, 101(6): 1222-1227. DOI: 10.1097/TP.0000000000001330.
|
[29] |
STEGALL MD, DIWAN T, RAGHAVAIAH S, et al. Terminal complement inhibition decreases antibodymediated rejection in sensitized renal transplant recipients[J]. Am J Transplant, 2011, 11(11): 2405-2413. DOI: 10.1111/j.1600-6143.2011.03757.x.
|
[30] |
MARKS WH, MAMODE N, MONTGOMERY RA, et al. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial[J]. Am J Transplant, 2019, 19(10): 2876- 2888. DOI: 10.1111/ajt.15364.
|
[31] |
JORDAN SC, CHOI J, KIM I, et al. Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade[J]. Transplantation, 2017, 101(1): 32-44. DOI: 10.1097/TP.0000000000001452.
|
[32] |
JORDAN SC, AMMERMAN N, CHOI J, et al. Interleukin-6: an important mediator of allograft injury[J]. Transplantation, 2020, 104(12): 2497-2506. DOI: 10.1097/TP.0000000000003249.
|
[33] |
VO AA, CHOI J, KIM I, et al. A phase I/Ⅱ trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients[J]. Transplantation, 2015, 99(11): 2356- 2363. DOI: 10.1097/TP.0000000000000741.
|
[34] |
ORANDI BJ, LUO X, MASSIE AB, et al. Survival benefit with kidney transplants from HLA-incompatible live donors[J]. N Engl J Med, 2016, 374(10): 940-950. DOI: 10.1056/NEJMoa1508380.
|
[35] |
MANOOK M, KOESER L, AHMED Z, et al. Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis[J]. Lancet, 2017, 389(10070): 727-734. DOI: 10.1016/S0140-6736(16)31595-1.
|
[36] |
CLAYTON PA, COATES PT. Are sensitized patients better off with a desensitization transplant or waiting on dialysis?[J]. Kidney Int, 2017, 91(6): 1266-1268. DOI: 10.1016/j.kint.2017.04.004.
|
[37] |
KAHWAJI J, SINHA A, TOYODA M, et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin[J]. Clin J Am Soc Nephrol, 2011, 6(12): 2894-2900. DOI: 10.2215/CJN.03710411.
|
[38] |
KO EJ, YU JH, YANG CW, et al. Clinical outcomes of ABO- and HLA-incompatible kidney transplantation: a nationwide cohort study[J]. Transpl Int, 2017, 30(12): 1215-1225. DOI: 10.1111/tri.12979.
|